ATRC
AtriCure, Inc. · NASDAQ
- Sector Health Technology
- Industry Medical Specialties
- Website atricure.com
- Employees(FY) 1050
- ISIN US04963C2098
Performance
-6.31%
1W
-15.47%
1M
+6.63%
3M
+44.91%
6M
-13.93%
YTD
-10.9%
1Y
Profile
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Technical Analysis of ATRC 2024-12-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-28 07:35
- 2024-11-20 08:00
- 2024-11-19 19:00
- 2024-11-07 08:00
- 2024-11-06 19:00
- 2024-11-01 07:51
- 2024-10-31 07:07
AtriCure Third Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-10-30 11:04
- 2024-10-30 10:19
Q3 2024 AtriCure Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-10-30 03:12
- 2024-10-29 19:00
- 2024-10-29 17:10
- 2024-10-29 16:07
AtriCure: Q3 Earnings Snapshot(Associated Press Finance)
- 2024-10-29 16:01
AtriCure Reports Third Quarter 2024 Financial Results(Business Wire)
- 2024-10-29 04:01
AtriCure Reports Third Quarter 2024 Financial Results(Businesswire)
- 2024-10-28 08:00
- 2024-10-27 20:00
- 2024-10-16 12:11
- 2024-10-15 08:00
- 2024-10-14 20:00
- 2024-10-13 09:25
- 2024-10-11 10:30
- 2024-10-08 08:00
AtriCure to Announce Third Quarter 2024 Financial Results(Business Wire)
- 2024-10-07 20:00
- 2024-10-01 10:51
AtriCure Granted CE Mark for EnCompass Clamp(MT Newswires)
- 2024-10-01 08:00
AtriCure Receives CE-Mark for the EnCompass® Clamp(Business Wire)
- 2024-09-30 20:00
AtriCure Receives CE-Mark for the EnCompass Clamp(Businesswire)
- 2024-09-18 10:43
- 2024-09-16 08:12
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?(Simply Wall St.)
- 2024-08-28 12:13
Page 1 of 8
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.